Company intelligence / Profile preview
Reglagene
Tucson, Arizona, United Statesreglagene.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Reglagene's lead candidate RGN6024 is a tubulin inhibitor demonstrating 84% tumor growth reduction in preclinical glioblastoma models, superior brain penetration compared to standard care temozolomide, and anticipated IND filing around 2023-2024 with clinical trials planned for mid-2024.[2][3][4]
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Viva BioInnovator
Beyond the preview
Go deeper on Reglagene.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reglagene.